Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 4/20 | 0.34 |
| ▸ | F2 | P00734 | 2/20 | 0.33 |
| ▸ | F12 | P00748 | 2/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.31 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4130555 | 0.87 | CYP2C19 (0.34) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4143412 | 0.85 | POLB (0.36) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4138908 | 0.83 | LMNA (0.33) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4138429 | 0.82 | KCNA5 (0.34) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4147814 | 0.82 | KCNA5 (0.34) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4143846 | 0.81 | KCNH2 (0.33) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4143332 | 0.80 | — | — | |
| SCHEMBL4696171 | 0.80 | KCNA5 (0.33) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4138223 | 0.80 | KCNA5 (0.34) | CYP2C19POLBCYP3A4CYP2C9KCNA5 | |
| SCHEMBL4152647 | 0.80 | KCNA5 (0.34) | CYP2C19POLBCYP3A4CYP2C9KCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2009-01-15 | — | — | US | disclosed |
| US-7439253-B2 | Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | NOVEXEL (FR) | 2008-10-21 | — | — | US | disclosed |
| EP-1569935-B1 | HETEROCYCLIC COMPOUNDS, PREPARATION METHOD THEREOF AND USE OF SAME AS MEDICAMENTS, SUCH AS ANTI-BACTERIAL MEDICAMENTS AND BETA-LACTAMASE INHIBITORS | NOVEXEL (FR) | 2008-08-20 | — | — | EP | disclosed |
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | AVENTIS PHARMA S.A. (FR) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157826-A1 | Novel heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors | GAA, ALPI, GANAB | CYP2C19 119/4885POLB 387/4885CYP3A4 559/4885 |
| US-20090018329-A1 | NOVEL HETEROCYCLIC COMPOUNDS, THEIR PREPARATION AND THEIR USE AS MEDICAMENTS, IN PARTICULAR AS ANTIBACTERIALS AND BETA-LACTAMASE INHIBITORS | GAA, GANAB, ALPI | CYP2C19 133/4885POLB 319/4885CYP3A4 568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.